VALANX
VALANX Biotech develops a protein conjugation platform called GoldenSite™ that enables site-specific modification of proteins for the creation of drug conjugates. The technology utilizes click-chemistry to achieve high homogeneity and stability in antibody-drug conjugates (ADCs) without the need for catalysts or enzymes. The company targets drug developers seeking to improve the therapeutic window and pharmacokinetics of next-generation biopharmaceuticals.
Visit websiteVienna, Austria
Biotechnology
Biopharmaceuticals
Synthetic Biology
Healthtech
Funding summary
- Total raised
- €5.3M
- Funding rounds
- 2
Investors in VALANX
Investors on record for VALANX. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like VALANX?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors